SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Mirum says Phase 3 AZURE-1 trial meets primary endpoint for brelovitug in chronic hepatitis delta

Mirum said Week 24 results in chronic hepatitis delta showed improved viral control and liver inflammation versus delayed treatment.

MIRM.O

Related stories